SEOUL, June 29 (Reuters) - South Korea approved its first domestically developed COVID-19 vaccine, manufactured by SK bioscience, for general public use following positive clinical data, authorities said on Wednesday (Jun 29).
The SKYCovione vaccine was authorised for a two-dose regimen on people aged 18 or older, with shots given four weeks apart, according to the Ministry of Food and Drug Safety.
In a phase III clinical trial of 4,037 adults, SKYCovione induced neutralising antibody responses against the SARS-CoV-2 parental strain, SK bioscience said in a statement.
It is not yet known how effective it is against Omicron and other COVID-19 variants.
The vaccine was jointly developed by the University of Washington's Institute for Protein Design, with the support of global drugmaker GlaxoSmithKline (GSK).
SK bioscience said it would seek authorisations for distribution of SKYCovione in other countries and through global vaccine sharing facility COVAX, and for emergency use listing at the World Health Organization.
South Korean authorities have agreed to a 200 billion won (US$155 million) deal to buy 10 million doses of the vaccine, which can be stored under normal refrigeration conditions, and previously said they expected it to be rolled out from the second half of the year.
SK bioscience is now looking into its possible use for booster shots, and planning trials for adolescents and children, it added.
Nearly 87 per cent of South Korea's 52 million population are fully vaccinated, with 65 per cent having also had a booster shot, according to the Korea Disease Control and Prevention Agency data.